Table 1.
Patient characteristics.
| Variables | n = 41 |
|---|---|
| Age (years), median (range) | 72 (46–84) |
| Sex (male/female), n | 32/9 |
| BW (kg), median (range) | 59 (38–85.9) |
| ⩾60 kg/<60 kg | 20/21 |
| Dose (12 mg/8 mg), median (range) | 22/19 |
| TNM stage (I/II/III/IV/IVa), n | 1/8/7/5/20 |
| BCLC stage (B/C), n | 13/28 |
| Vp (yes/no) | 6/35 |
| Vv (yes/no) | 3/38 |
| MVI (yes/no) | 7/34 |
| Leukocyte count (×104/µl), median (range) | 4700 (1470–10950) |
| Platelet count (×104/mm3), median (range) | 14.5 (4.2–39.4) |
| Albumin (g/dl), median (range) | 3.3 (2.4–4.8) |
| PT (%), median (range) | 80 (58–110) |
| Tbil (mg/dl), median (range) | 0.8 (0.3–2.2) |
| AST (IU/l), median (range) | 35 (14–214) |
| ALT (IU/l), median (range) | 26 (9–107) |
| γGTP (IU/l), median (range) | 83 (11–716) |
| AFP (ng/ml), median (range) | 1123 (0.5–2561000) |
| AFP-L3 (%), median (range) | 25.2 (0–85) |
| DCP (AU/l), median (range) | 1869 (16–418970) |
| Child Pugh grade (A/B), n | 34/7 |
| ALBI score | −2.06 (–1.06 to –3.37) |
| ALBI grade (1/2/3) | 6/34/1 |
| History of prior treatment (yes/no), n | |
| TACE | 32/9 |
| Sorafenib | 18/23 |
| Regorafenib | 10/31 |
| Etiology (presence/no), n | |
| HBV | 7/34 |
| HCV | 9/32 |
| HCV post SVR | 9/32 |
| Alcohol | 6/35 |
AFP, alpha-fetoprotein; ALBI, albumin-bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BW, body weight; DCP, des-gamma-carboxy pro- thrombin; FT, free triiodothyronine; γGTP, γ-glutamyl transpeptidase; HBV, hepatitis B virus; HCV, hepatitis C virus; PT, prothrombin time; SVR, sustained virologic response; TACE, transcatheter arterial chemoembolization.; TSH, thyroid-stimulating hormone.